» Articles » PMID: 31949110

Culture of Pulmonary Artery Endothelial Cells from Pulmonary Artery Catheter Balloon Tips: Considerations for Use in Pulmonary Vascular Disease

Abstract

Endothelial dysfunction is a hallmark of pulmonary arterial hypertension (PAH) but there are no established methods to study pulmonary artery endothelial cells (PAECs) from living patients. We sought to culture PAECs from pulmonary artery catheter (PAC) balloons used during right-heart catheterisation (RHC) to characterise successful culture attempts and to describe PAEC behaviour.PAECs were grown in primary culture to confluence and endothelial cell phenotype was confirmed. Standard assays for apoptosis, migration and tube formation were performed between passages three to eight. We collected 49 PAC tips from 45 subjects with successful PAEC culture from 19 balloons (39%).There were no differences in subject demographic details or RHC procedural details in successful unsuccessful attempts. However, for subjects who met haemodynamic criteria for PAH, there was a higher but nonsignificant (p=0.10) proportion amongst successful attempts (10 out of 19, 53%) unsuccessful attempts (nine out of 30, 30%). A successful culture was more likely in subjects with a lower cardiac index (p=0.03) and higher pulmonary vascular resistance (p=0.04). PAECs from a subject with idiopathic PAH were apoptosis resistant compared to commercial PAECs (p=0.04) and had reduced migration compared to PAECs from a subject with portopulmonary hypertension with high cardiac output (p=0.01). PAECs from a subject with HIV-associated PAH formed fewer (p=0.01) and shorter (p=0.02) vessel networks compared to commercial PAECs.Sustained culture and characterisation of PAECs from RHC balloons is feasible, especially in PAH with high haemodynamic burden. This technique may provide insight into endothelial dysfunction during PAH pathogenesis.

Citing Articles

Characteristic disease defects in circulating endothelial cells isolated from patients with pulmonary arterial hypertension.

Aulak K, Mavarakis L, Tian L, Paul D, Comhair S, Dweik R PLoS One. 2024; 19(10):e0312535.

PMID: 39466801 PMC: 11516004. DOI: 10.1371/journal.pone.0312535.


Emerging connectivity of programmed cell death pathways and pulmonary vascular remodelling during pulmonary hypertension.

Yuan M, Liu T, Cai A, Zhan Z, Cheng Y, Wang Q J Cell Mol Med. 2024; 28(16):e70003.

PMID: 39153207 PMC: 11330287. DOI: 10.1111/jcmm.70003.


Extrapulmonary manifestations of pulmonary arterial hypertension.

Singh N, Al-Naamani N, Brown M, Long G, Thenappan T, Umar S Expert Rev Respir Med. 2024; 18(3-4):189-205.

PMID: 38801029 PMC: 11713041. DOI: 10.1080/17476348.2024.2361037.


Targeted Rapamycin Delivery via Magnetic Nanoparticles to Address Stenosis in a 3D Bioprinted in Vitro Model of Pulmonary Veins.

Ning L, Zanella S, Tomov M, Amoli M, Jin L, Hwang B Adv Sci (Weinh). 2024; 11(26):e2400476.

PMID: 38696618 PMC: 11234432. DOI: 10.1002/advs.202400476.


Transcriptional profiles of pulmonary artery endothelial cells in pulmonary hypertension.

Singh N, Eickhoff C, Garcia-Agundez A, Bertone P, Paudel S, Tambe D Sci Rep. 2023; 13(1):22534.

PMID: 38110438 PMC: 10728171. DOI: 10.1038/s41598-023-48077-6.


References
1.
Ferrer E, Dunmore B, Hassan D, Ormiston M, Moore S, Deighton J . A Potential Role for Exosomal Translationally Controlled Tumor Protein Export in Vascular Remodeling in Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol. 2018; 59(4):467-478. PMC: 6178156. DOI: 10.1165/rcmb.2017-0129OC. View

2.
Zhou C, Francis C, Xu N, Stevens T . The role of endothelial leak in pulmonary hypertension (2017 Grover Conference Series). Pulm Circ. 2018; 8(4):2045894018798569. PMC: 6134503. DOI: 10.1177/2045894018798569. View

3.
Sa S, Gu M, Chappell J, Shao N, Ameen M, Elliott K . Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity. Am J Respir Crit Care Med. 2016; 195(7):930-941. PMC: 5387706. DOI: 10.1164/rccm.201606-1200OC. View

4.
Simonneau G, Montani D, Celermajer D, Denton C, Gatzoulis M, Krowka M . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018; 53(1). PMC: 6351336. DOI: 10.1183/13993003.01913-2018. View

5.
Nickel N, Spiekerkoetter E, Gu M, Li C, Li H, Kaschwich M . Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling. Am J Respir Crit Care Med. 2015; 191(11):1273-86. PMC: 4476518. DOI: 10.1164/rccm.201412-2291OC. View